Experimental clotting agent VMX-C001 tested with common blood thinners

NCT ID NCT06517563

Completed Knowledge-focused Sponsor: VarmX B.V. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tested an experimental drug called VMX-C001 in 16 healthy adults to see how it affects blood clotting when taken with common blood thinners like rivaroxaban and enoxaparin. The goal was to measure changes in various clotting tests, not to treat any disease. Because it was a small Phase 1 study in healthy people, it provides basic safety and activity data but does not suggest a new treatment yet.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VMX-C001 (an engineered human clotting factor)
What this could lead to: If successful, this could help develop ways to manage blood thinning in people taking certain medications, but this is very early research.
What could go wrong: This is a small, early-stage study in healthy volunteers, not patients. It only measures lab tests, not real-world outcomes. Results may not apply to people with clotting disorders.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COAGULATION DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

blood coagulation disease vascular hemostatic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COAGULATION DISORDER

Contacts and locations

Locations

ICON

Groningen, 9728 NZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.